Precigen (PGEN) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Precigen (NASDAQ: PGEN) recently:

• 11/8/2026 – Precigen was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 11/5/2026 – Precigen was given a new $12.00 price target by Raymond James Financial.
• 11/5/2026 – Precigen had its “market outperform” rating reaffirmed by Citigroup.
• 11/5/2026 – Precigen had its price target raised by Citizens Jmp from $11.00 to $12.00. They now have a “market outperform” rating on the stock.
• 10/31/2026 – Precigen was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/15/2026 – Precigen had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/5/2026 – Precigen was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/25/2026 – Precigen is now covered by B. Riley Financial. They set a “buy” rating and a $12.00 price target on the stock.
• 9/24/2026 – Precigen is now covered by B. Riley Financial. They set a “buy” rating and a $12.00 price target on the stock.

Precigen Price Performance

Shares of PGEN traded up $0.36 during trading hours on Monday, reaching $4.83. 5,211,886 shares of the company traded hands, compared to its average volume of 4,965,639. The stock has a market capitalization of $1.72 billion, a PE ratio of 48.35 and a beta of 1.01. The stock has a fifty day simple moving average of $6.98 and a 200 day simple moving average of $5.28. Precigen, Inc. has a fifty-two week low of $3.04 and a fifty-two week high of $8.98. The company has a quick ratio of 4.83, a current ratio of 5.58 and a debt-to-equity ratio of 1.12.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The firm had revenue of $74.15 million during the quarter, compared to the consensus estimate of $71.55 million. During the same quarter in the previous year, the company posted ($1.06) EPS. The firm’s revenue for the quarter was up 2437.6% on a year-over-year basis. As a group, research analysts predict that Precigen, Inc. will post 0.27 EPS for the current fiscal year.

Insider Transactions at Precigen

In related news, COO Rutul R. Shah sold 15,342 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total transaction of $115,065.00. Following the transaction, the chief operating officer owned 468,865 shares of the company’s stock, valued at approximately $3,516,487.50. This represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the sale, the director owned 17,100 shares in the company, valued at approximately $127,224. This trade represents a 91.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 235,000 shares of company stock valued at $1,751,400. Insiders own 41.40% of the company’s stock.